No Data
No Data
Express News | Belite Bio Shares Are Trading Higher After the Company Announced LBS-007 Was Granted FDA Fast-track Designation Status for Acute Leukemia
Express News | Lin Bioscience Receives U.S. FDA Fast Track Designation for Lbs-007
Maxim Group Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $110
Belite Bio Price Target Raised to $110 From $60 at Maxim
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Mereo Biopharma Group Plc (MREO) and Fate Therapeutics (FATE)
Belite Bio Is Maintained at Buy by HC Wainwright & Co.